BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17510350)

  • 1. Cancer. Converging on beta-catenin in Wilms tumor.
    Nusse R
    Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
    [No Abstract]   [Full Text] [Related]  

  • 2. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
    Major MB; Camp ND; Berndt JD; Yi X; Goldenberg SJ; Hubbert C; Biechele TL; Gingras AC; Zheng N; Maccoss MJ; Angers S; Moon RT
    Science; 2007 May; 316(5827):1043-6. PubMed ID: 17510365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
    Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-β-catenin signalling.
    Brauburger K; Akyildiz S; Ruppert JG; Graeb M; Bernkopf DB; Hadjihannas MV; Behrens J
    FEBS J; 2014 Feb; 281(3):787-801. PubMed ID: 24251807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms tumor genetics: a new, UnX-pected twist to the story.
    Huff V
    Cancer Cell; 2007 Feb; 11(2):105-7. PubMed ID: 17292822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex].
    Angers S
    Med Sci (Paris); 2007 Nov; 23(11):1025-7. PubMed ID: 18021721
    [No Abstract]   [Full Text] [Related]  

  • 7. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
    Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
    Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
    Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
    Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
    Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1).
    Tanneberger K; Pfister AS; Kriz V; Bryja V; Schambony A; Behrens J
    J Biol Chem; 2011 Jun; 286(22):19204-14. PubMed ID: 21498506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt signaling as a therapeutic target for cancer.
    Herbst A; Kolligs FT
    Methods Mol Biol; 2007; 361():63-91. PubMed ID: 17172707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.
    Su MC; Huang WC; Lien HC
    APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
    Rivera MN; Kim WJ; Wells J; Driscoll DR; Brannigan BW; Han M; Kim JC; Feinberg AP; Gerald WL; Vargas SO; Chin L; Iafrate AJ; Bell DW; Haber DA
    Science; 2007 Feb; 315(5812):642-5. PubMed ID: 17204608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atonal homolog 1 expression in lung cancer correlates with inhibitors of the Wnt pathway as well as the differentiation and primary tumor stage.
    Xu HT; Xie XM; Li QC; Liu SL; Dai SD; Liu Y; Wang EH
    APMIS; 2013 Feb; 121(2):111-9. PubMed ID: 23030416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.
    Han M; Rivera MN; Batten JM; Haber DA; Dal Cin P; Iafrate AJ
    Genes Chromosomes Cancer; 2007 Oct; 46(10):909-13. PubMed ID: 17620295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is WTX a suitable target for cancer therapy?
    Perotti D; Radice P
    Pediatr Blood Cancer; 2011 Apr; 56(4):682. PubMed ID: 21298763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.